Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 18, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ:GILD), Elan Corporation, plc (NYSE:ELN), Agilent Technologies Inc. (NYSE:A), Alkermes plc (NASDAQ:ALKS) and Hospira Inc. (NYSE:HSP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Gilead Sciences Inc. Research Report
On December 13, 2013, Gilead Sciences Inc. (Gilead) announced that the US Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera for use in certain virologically-suppressed adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. According to the Company, Complera combines a complete course of three antiretroviral medications into a single, once-daily tablet, and contains Gilead's Truvada®, which itself is a fixed-dose combination of two HIV medicines, and Janssen R&D Ireland's rilpivirine. "Complera is an effective single-pill therapy with a demonstrated safety profile, and has rapidly become an important option for appropriate HIV patients who are initiating antiretroviral treatment," said Calvin J. Cohen, MD, M.Sc., Research Director, Community Research Initiative of New England and an investigator on clinical trials of Complera. "The data supporting today's approval demonstrate Complera has the potential to help a broader range of HIV-infected patients who have achieved virologic control on another regimen." The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Elan Corporation, plc Research Report
On December 13, 2013, Elan Corp. (Elan) and Perrigo Company (Perrigo) announced that the Irish High Court has approved Perrigo's pending acquisition of Elan. Earlier on July 28, 2013, the two companies had entered into a transaction agreement pursuant to which Perrigo agreed to acquire Elan through the formation of a new Irish holding company, that has since been renamed Perrigo Company plc. (New Perrigo). Following the consummation of these transactions, both Perrigo and Elan will be wholly owned subsidiaries of New Perrigo. Perrigo Chairman, President and CEO Mr. Joseph C. Papa stated: "We are pleased with the Irish High Court's approval of the scheme of arrangement and expect to close the Elan transaction prior to the end of the year." The parties informed that they have now obtained all regulatory approvals required to complete the transaction, closing of which is expected to occur on December 18, 2013. The Full Research Report on Elan Corporation, plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Agilent Technologies Inc. Research Report
On December 9, 2013, Agilent Technologies Inc. (Agilent) announced that Microchip Technology Inc. (Microchip Technology) has adopted Agilent EEsof EDA's Model Builder Program and Model Quality Assurance software to create internal fabrication device model libraries or process design kits, modify external foundry libraries, and validate supported devices from internal and external sources. Brian Chen, Device Modeling Product Manager at Agilent EEsof EDA said, "We are particularly gratified to see that a large and growing number of fab-lite and fabless design houses, as well as IDMs like Microchip Technology, have chosen these products to create differentiation, increase operation efficiency, reduce time-to-market, and gain competitive advantage. With superior field support and significant R&D investment, we are committed to making these solutions the easy choice for device-modeling and foundry-interface organizations in semiconductor companies." The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Alkermes plc Research Report
On December 13, 2013, Alkermes plc (Alkermes) stock ended the day at $39.50, reflecting a 0.83% decline from the previous day's closing price of $39.83. The Company's stock went down by 1.27% over the past three trading days, almost in line with the Dow Jones Industrial Average which also declined by 1.36% during the same trading period. The Full Research Report on Alkermes plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Hospira Inc. Research Report
On December 13, 2013, Hospira Inc. (Hospira) stock ended the day at $39.88, 0.92% lower than the previous day's closing price of $40.25. The Company's stock went down by 3.88% over the past three trading days, compared to the Dow Jones Industrial Average which also went down by 1.36% during the same trading period. The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner